Related Experiment Video

Updated: Oct 11, 2025

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

33.8K

Promising Therapeutic Targets in Kidney Renal Clear Cell Carcinoma: PLXNA1 and PLXNB3

Can-Xuan Li1, Dan Long2, Quan Meng3

  • 1Department of Urology and Shenshan Medical Center, Memorial Hospital of Sun Yat-Sen University, Shanwei, China.

Cancer Biotherapy & Radiopharmaceuticals
|December 1, 2021
PubMed

Insights

This study identifies plexins as key players in kidney clear cell carcinoma (KIRC). PLXNA1 and PLXNB3 are highlighted as independent prognostic factors for KIRC patient survival.

Area of Science:

  • Oncology
  • Genetics
  • Bioinformatics

Background:

  • Kidney clear cell carcinoma (KIRC) is a significant health concern.
  • Understanding the molecular mechanisms driving KIRC progression is crucial for developing effective treatments.

Purpose of the Study:

  • To identify dysregulated plexin genes in KIRC.
  • To investigate the prognostic significance of plexins in KIRC.
  • To explore the potential therapeutic targets for KIRC.

Main Methods:

  • Utilized The Cancer Genome Atlas (TCGA) database for RNA-sequencing data and clinicopathological information.
  • Performed integrated bioinformatics analyses, including univariate and multivariate Cox regression.
  • Conducted drug sensitivity analysis.

Main Results:

  • Nearly all plexin gene family members were found to be dysregulated in KIRC.
  • PLXNA1 and PLXNB3 were identified as independent prognostic factors for overall survival in KIRC patients.
  • PLXNA1/B3 may promote KIRC progression via cancer signaling pathways, tumor immunity, and angiogenesis.

Conclusions:

  • PLXNA1 and PLXNB3 are significant independent prognostic factors in KIRC.
  • PLXNA1/B3 represent promising novel therapeutic targets for KIRC treatment.
  • Vemurafenib emerged as a potential drug for targeting PLXNA1/B3 in KIRC.
Keywords:
bioinformaticsdrug sensitivitykidney renal clear cell carcinomaplexins

More Related Videos

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium08:46

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium

Published on: September 1, 2015

9.9K
MISSION LentiPlex Pooled shRNA Library Screening in Mammalian Cells09:12

MISSION LentiPlex Pooled shRNA Library Screening in Mammalian Cells

Published on: December 21, 2011

18.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.1K